Dr Rimona Weil
Telephone:
Email:
Location:
- National Hospital for Neurology and Neurosurgery
GMC/GDC number:
6029150
Professional background
Dr Weil graduated from Downing College, Cambridge with a first class degree in medical sciences, before studying clinical medicine at University College London.
She trained in general medicine at the Hammersmith, Brompton and Whittington hospitals (MRCP in 2004). She trained in neurology at the Royal Free Hospital and the National Hospital for Neurology and Neurosurgery.
She is now a Wellcome Trust clinician scientist and honorary consultant neurologist at the National Hospital for Neurology and Neurosurgery. She runs clinics in cognitive disorders, movement disorders and general neurology and has a particular interest in hallucinations and cognitive disorders in Parkinson’s disease.
Specialties
Research interests
Dr Weil’s PhD research was at the Wellcome Trust Centre for Neuroimaging, UCL, where she examined the integration of visual signals in the healthy and damaged brain.
She was awarded a post-doctoral UCL excellence fellowship in 2014 to study visual changes in Parkinson’s disease.
She now leads a Wellcome-funded group that aims to shed light on how dementia happens in Parkinson’s disease, using visual perception measures and neuroimaging to detect early clues of cognitive involvement in Parkinson’s disease.
Publications
Recent publications:
• Zarkali A, McColgan P, Ryten M, Reynolds, Leyland LA … & Weil RS. Differences in network controllability and regional gene expression in Parkinson’s hallucinations. Brain 2020 in press.
• Weil RS. Visual dysfunction and Parkinson’s disease. Movement Disorders 2020 in press.
• O’Brien, JT, Taylor, JP, Ballard C, …. Weil RS & ffytche. Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. JNNP 2020:91(5)512-519.
• Thomas EC, Leyland LAL, Schrag AE, Lees AJ, Acosta Cabronero J & Weil RS. Brain iron deposition is linked with cognitive severity in Parkinson’s disease. JNNP 2020:91(4):418-425
• Zarkali A, McColgan P, Leyland LA, Lees AJ… & Weil RS, Fibre-specific white matter reductions in Parkinson’s hallucinations and visual dysfunction. Neurology. 2020:94(14):1525-1538
• Weil RS, Hsu JK, Darby RR, Soussand L, Fox MD. Neuroimaging Parkinson’s disease dementia: Connecting the dots. Brain Communications. 2019:1(1)fcz006.
• Zarkali A, Adams RA, Stamatios P, Leyland LA, Rees G, Weil RS. Increased weighting on prior knowledge in Lewy Body-associated visual hallucinations. Brain Communications. 2019:1(1)fcz007.
• Leyland LA, Bremner FD, Keane PA, Schrag AE and Weil RS. Visual tests predict dementia risk in Parkinson’s disease. Neurology Clinical Practice. 2020:10(1)29-39
• Weil RS, Winston JS, Leyland LA, et al. Neural correlates of early cognitive dysfunction in Parkinson’s disease. Annals of Clinical and Translational Neurology. 2019: 6(5):902-912
• Weil RS, Morris HR. REM sleep disorder–an early window into neurodegeneration? Brain 2019: 142(3):498-501
• Lanskey JH, McColgan P, Schrag AE, Acosta-Cabronero J, Rees G, Morris HR, Weil RS. Can Neuroimaging predict dementia in Parkinson’s disease? Brain 2018: 141(9):2545-2560